Bioqual Inc
OTC:BIOQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (6), the stock would be worth $63.5 (69% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.5 | $37.51 |
0%
|
| 3-Year Average | 6 | $63.5 |
+69%
|
| 5-Year Average | 5.7 | $59.88 |
+60%
|
| Industry Average | 6.4 | $67.35 |
+80%
|
| Country Average | 6.5 | $68.87 |
+84%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Bioqual Inc
OTC:BIOQ
|
33.5m USD | 3.5 | 74 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 9.7 | 87.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 7.2 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 7.5 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9.7 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 4.3 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.9 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 6.4 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
Bioqual Inc
Glance View
Bioqual, Inc. engages in the provision and development of medical research and consulting services to commercial clients and government laboratories. The company is headquartered in Rockville, Maryland. The firm also performs in vitro contract research services. The company is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The In vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. The firm provides its services to the federal government, universities and the life science and pharmaceutical industries.
